Edward L. Hipkiss

Cleveland Clinic — United States

Immunology and Microbiology · Life Sciences

13h-index4.4kcitations36works0.52yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(29), Immune Cell Function and Interaction(26), Cytokine Signaling Pathways and Interactions(16), Cancer Immunotherapy and Biomarkers(7), T-cell and B-cell Immunology(6)

Publications36 total

Ruxolitinib for Chronic Lung Allograft Dysfunction
American Journal of Transplantation·2025· 1 citedOpen Access
Clinical Utility of Methicillin-Resistant Staphylococcus aureus Nasal PCRs in Lung Transplant Recipients
American Journal of Transplantation·2025
Supplementary Figure 3 from Cyclophosphamide Augments Antitumor Immunity: Studies in an Autochthonous Prostate Cancer Model
2023Open Access
Supplementary Figure 2 from Cyclophosphamide Augments Antitumor Immunity: Studies in an Autochthonous Prostate Cancer Model
2023Open Access
Supplementary Figure Legends 1-7 from Cyclophosphamide Augments Antitumor Immunity: Studies in an Autochthonous Prostate Cancer Model
2023Open Access
Supplementary Figure 6 from Cyclophosphamide Augments Antitumor Immunity: Studies in an Autochthonous Prostate Cancer Model
2023Open Access
Supplementary Figure 6 from Cyclophosphamide Augments Antitumor Immunity: Studies in an Autochthonous Prostate Cancer Model
2023Open Access
Supplementary Figure 5 from Cyclophosphamide Augments Antitumor Immunity: Studies in an Autochthonous Prostate Cancer Model
2023Open Access
Supplementary Figure 4 from Cyclophosphamide Augments Antitumor Immunity: Studies in an Autochthonous Prostate Cancer Model
2023Open Access
Supplementary Figure 4 from Cyclophosphamide Augments Antitumor Immunity: Studies in an Autochthonous Prostate Cancer Model
2023Open Access
Supplementary Figure 2 from Cyclophosphamide Augments Antitumor Immunity: Studies in an Autochthonous Prostate Cancer Model
2023Open Access
Supplementary Figure Legends 1-7 from Cyclophosphamide Augments Antitumor Immunity: Studies in an Autochthonous Prostate Cancer Model
2023Open Access
Supplementary Figure 1 from Cyclophosphamide Augments Antitumor Immunity: Studies in an Autochthonous Prostate Cancer Model
2023Open Access
Supplementary Figure 5 from Cyclophosphamide Augments Antitumor Immunity: Studies in an Autochthonous Prostate Cancer Model
2023Open Access
Supplementary Figure 1 from Cyclophosphamide Augments Antitumor Immunity: Studies in an Autochthonous Prostate Cancer Model
2023Open Access
Data from Cyclophosphamide Augments Antitumor Immunity: Studies in an Autochthonous Prostate Cancer Model
2023Open Access
Data from Cyclophosphamide Augments Antitumor Immunity: Studies in an Autochthonous Prostate Cancer Model
2023Open Access
Supplementary Figure 7 from Cyclophosphamide Augments Antitumor Immunity: Studies in an Autochthonous Prostate Cancer Model
2023Open Access
Supplementary Figure 7 from Cyclophosphamide Augments Antitumor Immunity: Studies in an Autochthonous Prostate Cancer Model
2023Open Access
Supplementary Figure 3 from Cyclophosphamide Augments Antitumor Immunity: Studies in an Autochthonous Prostate Cancer Model
2023Open Access
page 1 of 2Next →

Frequent Co-authors

Charles G. Drake(31), Joseph F. Grosso(27), Derese Getnet(27), Monica V. Goldberg(26), Hung‐Rong Yen(24), George J. Netto(20), Kiyoshi Yoshimura(19), Angelo M. De Marzo(19), Satoshi Wada(18), Drew M. Pardoll(18), Tim Harris(15), Robert A. Anders(15), Drew M. Pardoll(10), Timothy Harris(8), Charles H. Maris(7), Tullia C. Bruno(6), Dallas B. Flies(5), Robert A. Anders(5), Satoshi Wada(4), Tim Harris(4)